Salvage Therapy for Ovarian Cancer

ONCOLOGY

Volumn 12, Issue 6, 1998, Pages 833-843

  Sabbatini, Paul ^b   Spriggs, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; LIPOSOME; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TAMOXIFEN CITRATE; TOPOTECAN;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; EDEMA; FEMALE; GASTROINTESTINAL TOXICITY; GENE THERAPY; HAIR LOSS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; REVIEW; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FORECASTING; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 0031808319     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Markman M, Hoskins W: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992.
2. Morris M, Gershenson DM, Wharton JT: Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first line-therapy. Gynecol Oncol 33:1-5, 1989.
3. Nicoletto MO, Tumolo S, Talamini R, et al: Surgical second look in ovarian cancer: A randomized study in patients with laparoscopic complete remission - a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol 15 994-999, 1997.
4. Bertelsen K, Jakobsen A, Stroyer I, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, Adriamycin, and cisplatin in advanced epithelial ovarian cancer A Danish Ovarian Study Group trial. Gynecol Oncol 49:30-36, 1993.
5. Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide. doxorubicin, and cisplatin in advanced ovarian cancer. Gynecol Oncol 45:284-289, 1992.
6. Gershenson DM, Mitchell MF, Atkinson N, et al: The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer. "Maintenance" therapy reconsidered. Gynecol Oncol 47:7-13, 1992.
7. Markman M, Hakes T, Barakat R, et al: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Center Institute Treatment Referral Center protocol 9103. Paclitaxel in refractory ovarian cancer J Clin Oncol 14:796-799, 1996.
8. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:s3-s10, 1997.
9. Levin L, Hryniuk WW: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987.
10. Schneider JG: Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 21:195-212, 1994
11. Markman M: Intraperitoneal chemotherapy. Semin Oncol 18:248-254, 1991.
12. Dedrick RL, Flessner MF: Pharmacokinetic problems in peritoneal drug adminstration: Tissue penetration and surface exposure. J Natl Cancer Inst 89:480-487, 1997.
13. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955, 1996.
14. Nederman T, Carlsson J: Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 13:131-135, 1984
15. Markman M, Reichman B, Hakes T, et al: Responses to second line cisplatin based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991.
16. Barakat R, Almadrones L, Venkatraman E, et al: A phase II trial of IP cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment (abstract). Proc Am Soc Clin Oncol 16:354a, 1997.
17. Menczer J, Ben-Baruch G, Rizel S, et al: Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission. Eur J Gynaecol Oncol 16:12-17, 1995.
18. Francis P, Rowinsky E, Schneider J, et al: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961-2967, 1995.
19. Braly P, Berek JS, Blessing JA, et al: Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: A phase II Gynecologic Oncology Group trial Gynecol Oncol 56:164-168, 1995.
20. Markman M, George M, Hakes T, et al: Phase 2 trial of intraperitoneal mitoxantrone in the management of refractory ovarian carcinoma. J Clin Oncol 8:146-150, 1990.
21. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
22. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J Clin Oncol 12:2301-2308, 1994.
23. Bajetta E, Di Leo A, Biganzoli L, et al: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum resistant disease. J Clin Oncol 14:2546-2551, 1996.
24. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996.
25. Creemers GJ, Bolis G, Scarfone G, et al: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996.
26. Kaye S, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer: Scottish Gynecology Cancer Trials Group. J Clin Oncol 14:2113-2119, 1996.
27. Ngan H, Choo Y, Cheung M, et al: A randomized study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35:221-227, 1989.
28. Conte P, Bruzzone M, Carnino F, et al: High dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14:351-356, 1996.
29. Levin L, Simon R, Hryniuk W: Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis. J Natl Cancer Inst 85:1732-1742, 1993.
30. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long term-results. J Clin Oncol 15:1302-1308, 1997
31. Stiff PJ, Bayer R, Kerger C, et al: High dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 15:1309-1317, 1997.
32. Abu-Rustum NR, Aghajanian C, Barakat R, et al. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:s62-s67, 1997.
33. Bristow RE, Lagasse LD, Karlan BY: Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Cancer 78:2049-2062, 1996.
34. Hoskins WJ, Rubin SC, Dulaney E: Influence of secondary cytoreduction at the time of second look laparotomy on the survival of patients with epithelial ovarian carcinoma Gynecol Oncol 34:365-371, 1989.
35. Segna RA, Dottino PR, Mandelli JP, et al: Secondary surgical cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11:434-439, 1993.
36. Vaccarello L, Rubin SC, Vlamis V, et al: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57:61-65, 1995.
37. Morris M, Gershenson DM, Wharton JT, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34:334-338, 1989.
38. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991.
39. Kavanagh J, Treukosol D, Edwards C, et al: Carboplatin reinduction after taxane in patients with platinum refractory ovarian cancer. J Clin Oncol 13:1584-1588, 1995.
40. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994.
41. Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel at 2 dose levels and filgrastim (G-CSF) at 2 doses in platinum pretreated epithelial ovarian cancer (abstract). Proc Am Soc Clin Oncol 15:280, 1996.
42. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997.
43. Kudelka AP, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14:1552-1557, 1996.
44. ten Bokkel Huinik W, Gore M, Carmichael J, et al: Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.
45. Creemers GJ, Gerrits CJH, Eckardt JR, et al: Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15:1087-1093, 1997.
46. Rose PG, Blessing JA, Mayer AR, et al: Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study (abstract) J Clin Oncol 16:405-410, 1998.
47. Kavanagh JJ, Kudelka AP, Gonzalez de Leon C, et al: Phase II study of docetaxel in patients with epithelial ovarian cancer refractory to platinum. Clin Cancer Res 2:837-842, 1996.
48. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:12-19, 1995.
49. Markman M, Hakes T, Resichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease J Clin Oncol 10:243-248, 1992.
50. Rustin GJS, Nelstrop AE, Crawford M, et al: Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125. J Clin Oncol 15:172-176, 1997
51. Ahlgren JD, Ellison NM, Gottlieb RJ, et at: Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase IT trials of the Mid-Atlantic Oncology Program J Clin Oncol 11:1957-1968, 1993.
52. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68:269-271, 1991.
53. Davidson SA, Rubin SC, Mychalczak B, et al: Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer Gynecol Oncol 51:349-354, 1993.
54. Cmelak AJ, Kapp DS: Long-term survival with whole abdominopelvic irradiation in platinum-refractory peristent or recurrent ovarian cancer. Gynecol Oncol 65:453-460, 1997.
55. Bergman AM, Ruiz van Haperen VW, Veerman G, et al: Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 2:521-550, 1996.
56. Whitacre CM, Zobrowska E, Gordon NH, et al: Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule dependent process. Cancer Res 57:1425-1428, 1997.
57. Barnes MN, Deshane JS, Rosenfeld M, et al: Gene therapy and ovarian cancer: A review. Obstet Gynecol 89:145-55, 1997.
58. Tanimoto H, Mehta KD, Parmley TH, et al: Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: Correlation to K-ras mutation. Gynecol Oncol 66:308-312, 1997.
59. McGuire W, Hoskins W, Brady M, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995.
60. Columbo N, Pitelli M, Parma G: Cisplatin dose intensity in advanced ovarian cancer: A randomized study of dose intense versus standard dose cisplatin monotherapy (abstract). Proc Am Soc Clin Oncol 12:255, 1993
61. Jakobsen A, Bertelsen K, Andersen J, et al: Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198, 1997.
62. Bella M, Cocconi G, Lotticci R, et al: Conventional versus high-dose intensity regimen of cisplatin in advanced ovarian carcinoma: A prospective randomized study (abstract). Proc Am Soc Clin Oncol 11:223, 1992.
63. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose vs low-dose and long vs short infusion. J Clin Oncol 12:2654-2666, 1994.
64. Markman M, Iseminger KA, Hatch KD, et al: Tamoxifen in platinum refractory ovarian cancer: A Gynecologic Oncology Group ancillary report. Gynecol Oncol 62:4-6, 1996.
65. Dimopoulos MA, Papadimitriou C, Gennatas C, et al: Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer. Ann Oncol 8:195-197, 1997.
66. Miglietta L, Amoroso D, Bruzzone M, et al: Paclitaxel plus ifosfamide in advanced ovarian cancer A multicenter phase II study. Oncology 54:102-107, 1997.
67. Nardi M, Della Giulla M, Pollera CF, et al: A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 38:298-301, 1996.
68. Lorusso V, Catino A, Leone B, et al: Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: A pilot study. J Clin Oncol 11:1952-1956, 1993.